Inovio announces positive interim phase 1 data for ino-4800 vaccine for covid-19

Plymouth meeting, pa., june 30, 2020 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on rapidly bringing to market precisely designed dna medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of...
INO Ratings Summary
INO Quant Ranking